StockData
Aquestive Therapeutics, Inc. logo

Aquestive Therapeutics, Inc. (AQST) stock

AQSTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 3/30
$3.70−0.06 (-1.60%)

Close on Nov 17, 2026Market cap $464.39MP/E –Yield –

Aquestive Therapeutics gross margin

Gross margin is gross profit as a percentage of revenue.

Aquestive Therapeutics's gross margin for the twelve months ending Jun 30, 2026 was 67.0%. For fiscal 2025 it was 58.3%, against 69.0% the year before. The highest annual figure on record is 71.7% in fiscal 2020.

Annual gross margin

PeriodPeriod endValueChange (pts)
FY2025Dec 31, 202558.3%−10.6
FY2024Dec 31, 202469.0%+10.1
FY2023Dec 31, 202358.8%−0.5
FY2022Dec 31, 202259.3%−12.4
FY2020Dec 31, 202071.7%+10.4
FY2019Dec 31, 201961.3%–

Quarterly gross margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q2 FY2026Jun 30, 202670.9%+16.5
Q1 FY2026Mar 31, 202676.0%+17.9
Q4 FY2025Dec 31, 202555.2%−6.8
Q3 FY2025Sep 30, 202564.8%−2.4
Q2 FY2025Jun 30, 202554.4%−23.1
Q1 FY2025Mar 31, 202558.1%−5.5
Q4 FY2024Dec 31, 202461.9%−2.7
Q3 FY2024Sep 30, 202467.2%+4.1
Q2 FY2024Jun 30, 202477.5%+27.5
Q1 FY2024Mar 31, 202463.6%+6.1
Q4 FY2023Dec 31, 202364.6%+14.2
Q3 FY2023Sep 30, 202363.1%+3.4
Q2 FY2023Jun 30, 202350.0%−10.5
Q1 FY2023Mar 31, 202357.5%−8.2
Q4 FY2022Dec 31, 202250.3%−16.5
Q3 FY2022Sep 30, 202259.7%−11.2
Q2 FY2022Jun 30, 202260.5%−14.7
Q1 FY2022Mar 31, 202265.7%+4.7
Q3 FY2021Sep 30, 202166.9%+2.9
Q2 FY2021Jun 30, 202170.9%−12.8
Q1 FY2021Mar 31, 202175.2%+17.0
Q4 FY2020Dec 31, 202061.0%+2.4
Q3 FY2020Sep 30, 202063.9%+1.3
Q2 FY2020Jun 30, 202083.7%+32.4
Q1 FY2020Mar 31, 202058.3%−14.0
Q4 FY2019Dec 31, 201958.6%–
Q3 FY2019Sep 30, 201962.6%–
Q2 FY2019Jun 30, 201951.3%–
Q1 FY2019Mar 31, 201972.3%–

More Aquestive Therapeutics figures

See a number that looks wrong?